ArticleClinical trials (London, England)2015
Harmonization and streamlining of research oversight for pragmatic clinical trials.
Article in Clinical trials (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Lessons Learned From a Practice-Based, Multisite Intervention Study With Nurse Participants.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2017Trial
- Regulatory Issues in Electronic Health Records for Adolescent HIV Research: Strategies and Lessons Learned.JMIR formative research · 2024Article
- Design, implementation, and inferential issues associated with clinical trials that rely on data in electronic medical records: a narrative review.BMC medical research methodology · 2023Review
- What went right during the COVID crisis: The capabilities of local actors and lasting innovations in oncology care and research.PLOS global public health · 2023Article
- Pragmatic clinical trial design in emergency medicine: Study considerations and design types.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2022Article
- Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.Contemporary clinical trials · 2022Article
- Justice and equity in pragmatic clinical trials: Considerations for pain research within integrated health systems.Learning health systems · 2022Article
- Responding to signals of mental and behavioral health risk in pragmatic clinical trials: Ethical obligations in a healthcare ecosystem.Contemporary clinical trials · 2022Article
- The ethical justification for inclusion of neonates in pragmatic randomized clinical trials for emergency newborn care.BMC pediatrics · 2019Article
- Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.Clinical trials (London, England) · 2019Article
- Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.BMC medical ethics · 2018Article
- Article
- Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation.BMC medical ethics · 2018Review
- Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.BMC medical research methodology · 2017Article
- Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative.Journal of the American Society of Nephrology : JASN · 2016Review
- Harms, benefits, and the nature of interventions in pragmatic clinical trials.Clinical trials (London, England) · 2015Article
- Exploring the ethical and regulatory issues in pragmatic clinical trials.Clinical trials (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
The oversight of research involving human participants is a complex process that requires institutional review board review as well as multiple non-institutional review board institutional reviews. This multifaceted process is particularly challenging for multisite research when each site independently completes all required local reviews. The lack of inter-institutional standardization can result in different review outcomes for the same protocol, which can delay study operations from start-up to study completion. Hence, there have been strong calls to harmonize and thus streamline the research oversight process. Although the institutional review board is only one of the required reviews, it is often identified as the target for harmonization and streamlining. Data regarding variability in decision-making and interpretation of the regulations across institutional review boards have led to a perception that variability among institutional review boards is a primary contributor to the problems with review of multisite research. In response, many researchers and policymakers have proposed the use of a single institutional review board of record, also called a central institutional review board, as an important remedy. While this proposal has merit, the use of a central institutional review board for multisite research does not address the larger problem of completing non-institutional review board institutional review in addition to institutional review board review—and coordinating the interdependence of these reviews. In this article, we describe the overall research oversight process, distinguish between institutional review board and institutional responsibilities, and identify challenges and opportunities for harmonization and streamlining. We focus on procedural and organizational issues and presume that the protection of human subjects remains the paramount concern. Suggested modifications of institutional review board processes that focus on time, efficiency, and consistency of review must also address what effect such changes have on the quality of review. We acknowledge that assessment of quality is difficult in that quality metrics for institutional review board review remain elusive. At best, we may be able to assess the time it takes to review protocols and the consistency across institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.